{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:44Z","timestamp":1792622624180,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Integrative Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.joim.2022.01.001","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T02:14:21Z","timestamp":1641262461000},"page":"126-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial"],"prefix":"10.1016","volume":"20","author":[{"given":"Yan-jun","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-li","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.joim.2022.01.001_b0005","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.joim.2022.01.001_b0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejvs.2007.01.004","article-title":"New antiplatelet strategies in atherothrombosis and their indications","volume":"34","author":"Fontana","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.joim.2022.01.001_b0015","unstructured":"Task Force on Myocardial Revascularization of the European Society of Cardiology, the European Association for Cardio-Thoracic Surgery, European Association for Percutaneous Cardiovascular Interventions; Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31(20):2501\u201355."},{"issue":"14","key":"10.1016\/j.joim.2022.01.001_b0020","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.joim.2022.01.001_b0025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.joim.2022.01.001_b0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0032-1301417","article-title":"High platelet reactivity and antiplatelet therapy resistance","volume":"38","author":"Linden","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"16","key":"10.1016\/j.joim.2022.01.001_b0035","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"issue":"9660","key":"10.1016\/j.joim.2022.01.001_b0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.joim.2022.01.001_b0045","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/eurheartj\/ehq321","article-title":"CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study","volume":"31","author":"Harmsze","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.joim.2022.01.001_b0050","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.joim.2022.01.001_b0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.joim.2022.01.001_b0060","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.joim.2022.01.001_b0065","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.joim.2022.01.001_b0070","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.joim.2022.01.001_b0075","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.joim.2022.01.001_b0080","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s11655-016-2532-z","article-title":"Effect of Wenhua Juanbi Recipe on expression of receptor activator of nuclear factor \u03baB ligand, osteoprotegerin, and tumor necrosis factor receptor superfamily member 14 in rats with collagen-induced arthritis","volume":"23","author":"Liu","year":"2017","journal-title":"Chin J Integr Med"},{"issue":"10","key":"10.1016\/j.joim.2022.01.001_b0085","doi-asserted-by":"crossref","first-page":"18597","DOI":"10.3390\/molecules201018597","article-title":"Qualitative and quantitative analysis of the major constituents in Shexiang Tongxin dropping pill by HPLC-Q-TOF-MS\/MS and UPLC-QqQ-MS\/MS","volume":"20","author":"Chen","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.joim.2022.01.001_b0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jep.2014.11.013","article-title":"Shexiang Tongxin dropping pill attenuates atherosclerotic lesions in ApoE deficient mouse model","volume":"159","author":"Xiong","year":"2015","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"10.1016\/j.joim.2022.01.001_b0095","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s11655-018-2559-4","article-title":"Effect of Shexiang Tongxin Dropping Pills on the immediate blood flow of patients with coronary slow flow","volume":"25","author":"Wang","year":"2019","journal-title":"Chin J Integr Med"},{"key":"10.1016\/j.joim.2022.01.001_b0100","first-page":"17","article-title":"International ethical guidelines for biomedical research involving human subjects","volume":"182","author":"Council for International Organizations of Medical Sciences","year":"2002","journal-title":"Bull Med Ethics"},{"key":"10.1016\/j.joim.2022.01.001_b0105","unstructured":"The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown & Co.; 1994: 253\u20136."},{"issue":"9749","key":"10.1016\/j.joim.2022.01.001_b0110","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"31\u201332","key":"10.1016\/j.joim.2022.01.001_b0115","first-page":"552","article-title":"Sample size calculation in clinical trials: part 13 of a series on evaluation of scientific publications","volume":"107","author":"R\u00f6hrig","year":"2010","journal-title":"Dtsch Arztebl Int"},{"issue":"3","key":"10.1016\/j.joim.2022.01.001_b0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1160\/TH06-06-0313","article-title":"Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets","volume":"97","author":"Sinauridze","year":"2007","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.joim.2022.01.001_b0125","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1160\/TH12-07-0486","article-title":"Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques","volume":"108","author":"Suades","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.joim.2022.01.001_b0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2016.03.004","article-title":"Possible roles of platelet-derived microparticles in atherosclerosis","volume":"248","author":"Wang","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.joim.2022.01.001_b0135","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.atherosclerosis.2006.12.004","article-title":"Increased circulating platelet-derived microparticles are associated with stent-induced vascular inflammation","volume":"196","author":"Inoue","year":"2008","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.joim.2022.01.001_b0140","first-page":"23","article-title":"High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance","volume":"3","author":"Garabedian","year":"2013","journal-title":"Cardiovasc Diagn Ther"},{"issue":"1","key":"10.1016\/j.joim.2022.01.001_b0145","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FJC.0b013e3181ffe8d0","article-title":"The effect of St John\u2019s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity","volume":"57","author":"Lau","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"10.1016\/j.joim.2022.01.001_b0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.joim.2022.01.001_b0155","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1253\/circj.CJ-09-0019","article-title":"Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan","volume":"73","author":"Jinnai","year":"2009","journal-title":"Circ J"},{"issue":"12","key":"10.1016\/j.joim.2022.01.001_b0160","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1172\/JCI27196","article-title":"Platelets in inflammation and atherogenesis","volume":"115","author":"Gawaz","year":"2005","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.joim.2022.01.001_b0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating platelets as mediators of immunity, inflammation, and thrombosis","volume":"122","author":"Koupenova","year":"2018","journal-title":"Circ Res"},{"issue":"18","key":"10.1016\/j.joim.2022.01.001_b0170","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2013-11-462432","article-title":"Emerging roles for platelets as immune and inflammatory cells","volume":"123","author":"Morrell","year":"2014","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.joim.2022.01.001_b0175","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.2174\/1381612822666160607064118","article-title":"The role of platelets in cardiovascular disease: molecular mechanisms","volume":"22","author":"Papapanagiotou","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.joim.2022.01.001_b0180","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jjcc.2008.12.007","article-title":"Inflammatory biomarkers in coronary artery disease","volume":"53","author":"Zakynthinos","year":"2009","journal-title":"J Cardiol"},{"issue":"3","key":"10.1016\/j.joim.2022.01.001_b0185","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.2016.1128828","article-title":"A focus on inflammation as a major risk factor for atherosclerotic cardiovascular diseases","volume":"14","author":"Gregersen","year":"2016","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.joim.2022.01.001_b0190","doi-asserted-by":"crossref","first-page":"790263","DOI":"10.1155\/2013\/790263","article-title":"Antiatherosclerotic potential of clopidogrel: antioxidant and anti-inflammatory approaches","volume":"2013","author":"Hadi","year":"2013","journal-title":"Biomed Res Int"},{"issue":"65","key":"10.1016\/j.joim.2022.01.001_b0195","doi-asserted-by":"crossref","first-page":"108958","DOI":"10.18632\/oncotarget.22440","article-title":"Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro","volume":"8","author":"Qi","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.joim.2022.01.001_b0200","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3892\/mmr.2017.6963","article-title":"Protective effects of Shexiang Tongxin Dropping Pill on pituitrin-induced acute myocardial ischemia in rats","volume":"16","author":"Lin","year":"2017","journal-title":"Mol Med Rep"}],"container-title":["Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496422000012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095496422000012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:52:24Z","timestamp":1761864744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095496422000012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S2095496422000012"],"URL":"https:\/\/doi.org\/10.1016\/j.joim.2022.01.001","relation":{},"ISSN":["2095-4964"],"issn-type":[{"value":"2095-4964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet and myocardial protective effect of Shexiang Tongxin Dropping Pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Integrative Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joim.2022.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}